SOMERSET, NEW JERSEY -- (MARKET WIRE) -- October 11, 2006 -- Medicure Inc. (TSX: MPH)(AMEX: MCU),a cardiovascular focused biopharmaceutical company, today announced the launch of its U.S. sales organization to support the sales and marketing efforts for AGGRASTAT® injection (tirofiban hydrochloride). The Company has assembled a sales organization, with extensive experience in acute cardiovascular medicine and hospital based sales. Medicure acquired the exclusive U.S. rights to AGGRASTAT®, a glycoprotein (GP) IIb/IIIa inhibitor, in August 2006.
